In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes.

Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, 3050, Victoria, Australia.
Parasitology Research (Impact Factor: 2.85). 01/2008; 102(1):91-7. DOI: 10.1007/s00436-007-0729-y
Source: PubMed

ABSTRACT Resveratrol, a natural phytoalexin found mainly in grapes, possesses a variety of beneficial activities including anticancer, antimicrobial and antiviral. However, there is no information about its effects on kinetoplastid parasites such as Leishmania. Leishmania is a human pathogen responsible for a spectrum of diseases known as leishmaniases and a significant health problem in many parts of the world. In this study, we investigated effects of resveratrol and its hydroxylated analogues on Leishmania major, a causative agent of zoonotic cutaneous leishmaniasis in the Old World. Resveratrol showed antileishmanial activity against promastigotes in vitro and, more importantly, was effective against intracellular amastigotes, a parasite life stage infectious in humans, as detected in in vitro macrophage assay. The hydroxylated stilbenes tested in this study also showed antileishmanial activity against promastigotes, the most promising being 3,4,4',5'-tetrahydroxy-trans-stilbene. This compound showed excellent antileishmanial activity against extracellular promastigotes in vitro but not intracellular amastigotes. Our results suggest that resveratrol may be useful as a therapeutic agent to treat leishmaniasis and warrant its further assessment in animal models of disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Nine different β-thioxoketones of general formula R(1)C([double bond, length as m-dash]O)CH2C([double bond, length as m-dash]S)R(2) (R(1) = C6H5, R(2) = C6H5; R(1) = C6H5, R(2) = p-CF3C6H4; R(1) = p-MeOC6H4, R(2) = C6H5; R(1) = p-MeOC6H4, R(2) = p-CF3C6H4; R(1) = C5H4N, R(2) = C6H5; R(1) = p-IC6H4, R(2) = C6H5; R(1) = C6H5, R(2) = p-IC6H4; R(1) = C6H5, R(2) = C10H7 and R(1) = CH3, R(2) = C6H5) and their tris-substituted bismuth(iii) complexes having the general formula [Bi{R(1)C([double bond, length as m-dash]O)CHC([double bond, length as m-dash]S)R(2)}3] were synthesised and fully characterised. The solid state structure of [Bi{C5H4NC([double bond, length as m-dash]O)CHC([double bond, length as m-dash]S)C6H5}3] was determined by crystallography and revealed that the three β-thioxoketonato ligands are bound to bismuth(iii) centre in a bidentate fashion through O and S atoms. The bismuth(iii) complexes and the corresponding thioxoketones were assessed for their activity against H. pylori. All of the bismuth(iii) complexes were highly active against H. pylori having a MIC of greater than or equal to 3.125 μg mL(-1), while the free acids were essentially not toxic to the bacteria. The anti-leishmanial activity of all the bismuth(iii) β-thioxoketonates and the corresponding free acids were assessed against L. major promastigotes. The toxicity towards human fibroblast cells was also assessed. All of the free β-thioxoketones were selectively toxic to the L. major promastigotes displaying some potential as anti-leishmanial agents. Among these [C6H5C([double bond, length as m-dash]O)CH2C([double bond, length as m-dash]S)C6H5] and [C5H4NC([double bond, length as m-dash]O)CH2C([double bond, length as m-dash]S)C6H5] showed comparable activity to that of Amphotericin B, killing about 80% of the L. major promastigotes at a concentration of 25 μM (6.0 μg mL(-1)). The bismuth(iii) β-thioxoketonate complexes were toxic to both the L. major promastigotes and fibroblast cells at high concentrations, but gave no improvement in anti-leishmanial activity over the free β-thioxoketones.
    Dalton Transactions 11/2013; · 4.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In seeking new drugs for the treatment of the parasitic disease Leishmaniasis, an extensive range of organometallic antimony(v) dicarboxylates of the form [SbR3(O2CR')2] have been synthesised, characterised and evaluated. The organometallic moieties (R) in the complexes vary in being Ph, tolyl (o, m or p), or benzyl. The carboxylates are predominantly substituted benzoates with some compounds incorporating acetato or cinnamato ligands. The crystal structures of [Sb(p-Tol)3(O2CC6H2-3,4,5-(OMe)3)2]·0.5PhMe and [SbPh3(m-CH3C6H4CH2CO2)2] were determined and shown to adopt a typical trigonal pyramidal geometry, being monomeric with a five coordinate Sb centre. In total, the biological activity of 26 Sb(v) compounds was assessed against the Leishmania major parasite, and also human fibroblast skin cells to give a measure of general toxicity. Of these, 11 compounds (predominantly substituted benzoates with m- or p-tolyl ligands) proved to be highly effective against the parasite amastigotes at concentrations of 0.5-3.5 μM, while being non-toxic towards the mammalian cells at levels below 25 μM, making them highly promising drug candidates.
    Dalton Transactions 09/2013; · 4.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGR), an NADPH dependant enzyme catalyzes the synthesis of mevalonic acid from HMG-CoA required for isoprenoid biosynthesis. The HMGR gene from Leishmania donovani was cloned and expressed. Genome analysis of L. donovani revealed that HMGR gene having an open reading frame of 1,305 bp encodes a putative protein of 434 amino acids. LdHMGR showed optimal activity at pH 7.2 and temperature 37 °C. Kinetic analysis of this enzyme revealed Km values of 35.7 ± 2.5 μM for (R,S)-HMG-CoA and 70 ± 7.9 μM for the cofactor NADPH. On tryptophan fluorescence quenching, the Stern Volmer constant (Ksv), binding constant (Ka) and protein:cofactor stoichiometry for interaction of NADPH cofactor with the enzyme were found to be 6.0 ± 0.7 M(-1), 0.17 μM and 0.72 respectively. Polyclonal anti-rat HMGR antibody detected a band of ∼45 kDa in all phases of promastigote growth. Biophysical analysis of the secondary structure of LdHMGR confirmed the presence of 25.7 ± 0.35 % alpha helicity. Thermal denaturation studies showed extreme stability of the enzyme with 60 % helical structure retained at 90 °C. Statins (simvastatin and atorvastatin) and non-statin (resveratrol) effectively inhibited the growth of L. donovani promastigotes as well as the catalytic activity of the recombinant LdHMGR. Atorvastatin was found to be most potent antileishmanial inhibitor with an IC50 value of 19.4 ± 3.07 μM and a very lower concentration of 315.5 ± 2.1 nM was enough to cause 50 % recombinant LdHMGR enzyme inhibition suggesting direct interaction with the rate limiting enzyme of the ergosterol biosynthetic pathway. Exogenous supplementation of ergosterol in case of atorvastatin and resveratrol treated cells caused complete reversal of growth inhibition whereas simvastatin was found to be ergosterol refractory. Cholesterol supplementation however, failed to overcome growth inhibition in all the cases. Overall our study emphasizes on exploring LdHMGR as a potential drug target for the development of novel antileishmanial agents.
    Microbial Pathogenesis 11/2013; · 1.97 Impact Factor


Available from
May 21, 2014